Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00.
Rostislav Christov Raykov also recently made the following trade(s):
- On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The stock was acquired at an average cost of C$3.87 per share, with a total value of C$96,840.00.
- On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average price of C$8.52 per share, for a total transaction of C$6,779.05.
Fennec Pharmaceuticals Stock Up 0.1 %
Shares of TSE FRX traded up C$0.01 during trading on Wednesday, hitting C$8.77. 1,602 shares of the company traded hands, compared to its average volume of 1,012. The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The business's fifty day moving average is C$7.75 and its 200 day moving average is C$7.63. The firm has a market capitalization of C$239.95 million, a price-to-earnings ratio of 87.70 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$5.65 and a fifty-two week high of C$15.20.
Analyst Ratings Changes
Separately, Stephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Check Out Our Latest Stock Report on FRX
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
